相关实验视频

Updated: Jun 23, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

在患有2型糖尿病的人群中,GLP-1RA疗法增加了循环血管再生细胞含量

Brady Park^1,2,3,4, Aishwarya Krishnaraj^1,2,3,4, Hwee Teoh^1,2,3,5

¹Division of Cardiac Surgery, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.

American journal of physiology. Heart and circulatory physiology

|June 14, 2024

概括

类似葡萄糖类-1受体激活剂 (GLP-1RAs) 在2型糖尿病患者中增加血管再生原生细胞. 这种疗法还可以减少炎症,这可能解释了它对心血管的好处.

科学领域:

心血管医学心血管医学
内分泌学在内分泌学.
再生医学是一种再生医学.

背景情况:

葡萄糖类-1受体激动剂 (GLP-1RAs) 和-葡萄糖共运输体-2 (SGLT2) 抑制剂被推用于2型糖尿病 (T2D) 和相关心血管/疾病.
之前的研究表明,SGLT2抑制剂增加了冠状动脉疾病的T2D患者的血管再生 (VR) 原始细胞.

研究的目的:

分析GLP-1RA治疗,SGLT2抑制剂治疗或两者都没有的T2D患者的循环VR原始细胞含量.
探索GLP-1RA疗法的心血管代谢益处背后的潜在机制.

主要方法:

对ORIGINS-RCE CardioLink-13研究 (NCT05253521) 的特异性次分析,该研究涉及92名T2D患者.
分类为组:GLP-1RA使用者 (n=20),没有GLP-1RA的SGLT2抑制剂使用者 (n=42) 和没有治疗 (n=30).
测量循环的VR原生细胞 (ALDHhiSSClow和ALDHhiSSClowCD133+) 和亲炎性颗粒细胞前体细胞 (ALDHhiSSChi).

主要成果:

与"既不治疗"组相比,GLP-1RA组的循环VR原始细胞数量较高 (P=0.02) 和与SGLT2抑制剂组相比的水平 (P=0.25).
GLP-1RA组表现出明显较低的亲炎性粒细胞前体细胞数量与"没有治疗"组相比 (P=0.031).
这些发现表明GLP-1RAs可能会增强血管修复和减少炎症.

结论:

在患有T2D的个体中,GLP-1RA治疗与循环VR原生细胞的增加和粒细胞前体驱动炎症的减少有关.
这些效应可能代表了新的机制,有助于GLP-1RAs的心血管代谢益处.
需要进一步的随机临床试验来确认增强VR原始细胞含量的治疗价值.

关键词:

它是GLP-1受体激动剂.心脏代谢风险心脏代谢风险这是一种炎症炎症炎症炎症.原始细胞是原始细胞.血管再生血管再生

更多相关视频

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...